In the News
ICON experts frequently author or contribute to industry trade press.
Filter media articles by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category.
-
Using Economic Models to Gain Early Access
Early access schemes demand new ways of performing health economic evaluations. This means developing health economic models early to evaluate gaps and determine what level of investment makes sense. ICON's Nancy Risebrough and Mia Malmenas share insights in this Pharmafocus article.
-
Ready or Not, Medtech Braces For New EU Landscape
An article based on ICON’s session at the MedTech Conference in Philadelphia, featuring commentary from our expert, Vicki Anastasi, on preparations for the new EU Medical Device Regulation (MDR) and In Vitro Diagnostic Medical Device Regulation (IVDR) set to take effect in May 2020.
-
What ICER Pricing Would Mean for U.S. Drug Spend
The Institute for Clinical and Economic Review (ICER) is a major force in payer–manufacturer price negotiations. In a 2018 ICON plc survey of more than 20 U.S. payers, more than three quarters of respondents said that they would use an ICER cost-effectiveness threshold as a basis for negotiating a rebate contract. Read more from ICON's Nathan White, Adam Johns, and Eric Latch in the September 2018 issue of Managed Care.
-
CROs Must Be Aware Of Threat Posed By Big Tech
ICON’s CEO Steve Cutler discusses the impact of biotech funding and disruptive tech providers in this Scrip article.
-
Global Outsourcing Strategies
Colin Stanley, President, ICON Functional Services outlines how the market for outsourcing continues to grow including the types of outsourcing models sponsors have to choose from in this article in Contract Pharma.
-
The Path To A Successful Digital Trial
Transforming Clinical Trials: The Path To A Successful Digital Trial. A Thought Leadership article in Scrip Pharma Intelligence by Marie Mc Carthy, Senior Director Product Innovation, ICON and Chen Admati, Head of Intel Pharma Analytics Platform, Intel.
-
Adaptive Designs: Smarter Development Programmes for Oncology
A thought leadership article by Parvin Fardipour and Alan Phillips in Pharmafocus, which reviews the different types of adaptive trial designs that have been deployed in oncology trials to good effect, and discusses how they have changed the development paradigm.
-
Stakeholder Dialogue in Europe’s Adaptive Pathways Pilot
Get insights on the how the 3 principles of EMA’s adaptive pathways have worked in practice and what to expect for future accelerated access in Europe in this Pharmaceutical Market Europe (PME) edition.
-
Challenges in Clinical Trials
Steve Cutler, outlines some of the challenges to successful clinical trials in this PharmaTimes artice.
-
Device Certification and Recertification
ICON experts Vicki Anastasi and Karen Hill outline a three-step approach in this MD+DI article to identify products with the highest commercial value, helping you prioritize your medical and IVD devices for compliance with the new MDR and IVDR.
